SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

OneSource Specialty Pharma, Formycon partner for biosimilar manufacturing

14 Jul 2026 Evaluate

OneSource Specialty Pharma has entered into a strategic manufacturing partnership with Formycon AG (Formycon), an independent biosimilar developer headquartered in Munich, for biosimilars. Under the partnership, the company will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore. The collaboration brings together Formycon’s Biosimilar development excellence with the company’s end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.

The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model - that the company is specifically positioned to deliver.

Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. The company complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.

Onesource Specialty Share Price

1727.45 37.85 (2.24%)
28-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1977.20
Dr. Reddys Labs. 1135.65
Cipla 1444.65
Lupin 2394.70
Zydus Lifesciences 1099.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: